Antiviral drug Favipiravir investigated as a possible COVID-19 treatment for at-home recovery in PRINCIPLE trial
On Apr. 8, 2021, Oxford University announced that favipiravir was to be investigated in the UK as part…
On Apr. 8, 2021, Oxford University announced that favipiravir was to be investigated in the UK as part…
On Mar. 31, 2021, the National Institutes of Health (NIH) announced that an investigational vaccine designed to protect…
On Mar. 30, 2021, CureVac and Celonic Group announced their partnership for the production of CureVacメs mRNA-based COVID-19…
On Mar. 26, 2021, Pfizer and BioNTech announced that the European Medicines Agency (EMA) approved storage of COMIRNATYᆴ…
On Mar. 26, 2021, BioNTech announced that the European Medicines Agency (EMA) approved the manufacturing of the COVID-19…
On Mar. 26, 2021, the FDA issued an emergency use authorization (EUA) to the Twist Bioscience for their…
On Mar. 18, 2021, XPhyto and 3a-diagnostics announced the European approval of its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test…
On Mar. 16, 2021, Moderna announced that the first participants had been dosed in the Phase 2/3 study,…
On Mar. 15, 2021, Moderna announced that the first participants had been dosed in the Phase 1 study…
On Mar. 15, 2021, Twist Bioscience announced that it had started shipping its new synthetic RNA reference controls,…
On Mar. 9, 2021, Agilent Technologies announced the launch of a real-time reverse transcription (qRT) PCR-based diagnostic kit…
On Mar. 5, 2021, Merck and Ridgeback Biotherapeutics, announced preliminary results from Ridgebackメs Phase 2a randomized, double-blind, placebo-controlled…
On Mar. 5, 2021, Moderna announced that Takeda Pharmaceutical submitted a New Drug Application (NDA) to the Government…
On Mar. 4, 2021, CureVac and Novartis announced an initial agreement for the manufacturing of CureVacメs COVID-19 vaccine…
On Mar. 3, 2021, Pfizer and BioNTech, in partnership with UNICEF, announced the arrival of the first doses…
On Feb. 22, 2021, Amyris announced highly promising preliminary data in a pre-clinical study of its ribonucleic acid…
On Feb. 17, 2021, BioNTech announced an agreement with the European Commission (EC) to supply an additional 200…
On Feb. 12, 2021, CureVac announced initiation of a rolling submission with the European Medicines Agency (EMA) for…
On Feb. 10, 2021, BioNTech announced they had increased their manufacturing capacity in Marburg, Germany to up to…
On Feb. 3, 2021, Moderna announced that the Singapore Health Sciences Authority (HSA) had approved the interim authorization…
On Feb. 2, 2021, GlaxoSmithKline and CureVac announced a new タ150m collaboration, building on their existing relationship, to…
On Feb. 1, 2021, Pfizer and BioNTech announced that preclinical data in non-human primate and mouse models from…
On Jan. 29, 2021, OraSure Technologies announced its OMNIgeneᆴᄋORAL (OM-505) saliva collection kit, a product of subsidiary DNA…
On Jan. 25, 2021, Moderna announced results from in vitro neutralization studies of sera from individuals vaccinated with…
On Jan. 21, 2021, Moderna announced that the first participant has been dosed in the Phase 1/2 study…
On Jan. 14, 2021, Twist Bioscience announced that it had started shipping its new synthetic RNA reference controls,…
On Jan. 11, 2021, Moderna announced that it was expanding its pipeline of innovative vaccines with three new…
On Jan. 8, 2021, the Medicines and Healthcare products Regulatory Agency (MHRA) announced it had accepted the recommendation…
On Jan. 8, 2021, BioNTech announced that it was in talks with the European Commission (EC) about an…
On Jan. 7, 2021, Twist Bioscience announced it would supply the U.S. Centers for Disease Control and Prevention…